Brought to you by 
Novo Nordisk signs diabetes deal with Cellartis, Lund Univ.
13 Nov 2008
Executive Summary
Stem cell company Cellartis AB, Novo Nordisk AS, and Lund University have signed an agreement involving the development of insulin-producing cell therapies using human embryonic stem cells.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novo Nordisk signs diabetes deal with Cellartis, Lund Univ.
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice